152 related articles for article (PubMed ID: 21626328)
1. Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.
Yang H; Lin M; Xiong F; Yang Y; Nie X; McNutt MA; Zhou R
Surg Today; 2011 Jun; 41(6):810-7. PubMed ID: 21626328
[TBL] [Abstract][Full Text] [Related]
2. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
[TBL] [Abstract][Full Text] [Related]
3. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma.
Yang H; Xiong F; Qi R; Liu Z; Lin M; Rui J; Su J; Zhou R
J Surg Oncol; 2010 Apr; 101(5):363-9. PubMed ID: 20358632
[TBL] [Abstract][Full Text] [Related]
4. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
Meng F; Tan S; Liu T; Song H; Lou G
Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
[TBL] [Abstract][Full Text] [Related]
5. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
6. LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma.
Yang H; Zhai G; Ji X; Xiong F; Su J; McNutt MA
PLoS One; 2012; 7(4):e34984. PubMed ID: 22509374
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo.
Yang H; Xiong F; Wei X; Yang Y; McNutt MA; Zhou R
Cancer Lett; 2010 Aug; 294(2):236-44. PubMed ID: 20202745
[TBL] [Abstract][Full Text] [Related]
8. LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients.
Cheng X; Zheng Z; Bu Z; Wu X; Zhang L; Xing X; Wang X; Hu Y; Du H; Li L; Li S; Zhou R; Wen XZ; Ji JF
PLoS One; 2015; 10(4):e0121559. PubMed ID: 25849595
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study.
Meng F; Luo C; Hu Y; Yin M; Lin M; Lou G; Zhou R
Int J Gynecol Pathol; 2010 Nov; 29(6):587-93. PubMed ID: 20881850
[TBL] [Abstract][Full Text] [Related]
10. LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinoma.
Zhai G; Yan K; Ji X; Xu W; Yang J; Xiong F; Su J; McNutt MA; Yang H
PLoS One; 2012; 7(9):e45290. PubMed ID: 22984631
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
[TBL] [Abstract][Full Text] [Related]
12. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma.
Meng FL; Yin MZ; Song HT; Yang H; Lou G; Zhou RL
Int J Gynecol Cancer; 2010 Jul; 20(5):745-50. PubMed ID: 20966643
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.
Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R
PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860
[TBL] [Abstract][Full Text] [Related]
14. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.
Peng C; Zhou RL; Shao GZ; Rui JA; Wang SB; Lin M; Zhang S; Gao ZF
World J Gastroenterol; 2005 May; 11(18):2704-8. PubMed ID: 15884107
[TBL] [Abstract][Full Text] [Related]
15. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
16. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma.
Yang Y; Yang H; McNutt MA; Xiong F; Nie X; Li L; Zhou R
Oncol Rep; 2008 Nov; 20(5):1077-83. PubMed ID: 18949404
[TBL] [Abstract][Full Text] [Related]
17. Reduced expression of argininosuccinate lyase is closely associated with postresectional survival in hepatocellular carcinoma: an immunohistochemistry study of 61 cases.
Yang H; Zhai G; Ji X; Su J; Lin M
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):602-6. PubMed ID: 22531684
[TBL] [Abstract][Full Text] [Related]
18. Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinoma.
Roy G; Roy P; Bhattacharjee A; Shahid M; Misbah M; Gupta S; Husain M
Int J Biol Markers; 2018 Aug; 33(3):283-292. PubMed ID: 29882487
[TBL] [Abstract][Full Text] [Related]
19. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
[TBL] [Abstract][Full Text] [Related]
20. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma.
Wu L; Li L; Meng S; Qi R; Mao Z; Lin M
J Gastroenterol Hepatol; 2013 Feb; 28(2):365-8. PubMed ID: 23339388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
